Table 3.
Validation cohort clinical and demographic characteristics
| Stroke (S, n = 47) |
Normal (N, n = 31) |
P Values |
||||||
|---|---|---|---|---|---|---|---|---|
| Male (SM; n = 19) |
Female (SF; n = 28) |
Male (NM; n = 13) |
Female (NF; n = 18) |
Main Test | S vs. N | SM vs. SF | NM vs. NF | |
| aAge, mean ± SD | 71.3 ± 15 | 72.3 ± 18.1 | 60.2 ± 11.1 | 57.2 ± 9.4 | <0.001* | <0.001* | 0.804 | 0.427 |
| bAfrican American, n (%) | 1 (5.3) | 1 (3.6) | 3 (23.1) | 3 (16.7) | 0.143 | |||
| bCaucasian, n (%) | 18 (94.7) | 27 (96.4) | 10 (76.9) | 15 (83.3) | 0.143 | |||
| cNIHSS, mean ± SD | 7.7 ± 6.9 | 8.9 ± 7.4 | 0.597 | |||||
| cInfarct volume, cm3, mean ± SD | 23.4 ± 20.9 | 16.8 ± 21.2 | 0.413 | |||||
| cTime to blood draw, min, mean ± SD | 584 ± 397 | 530 ± 398 | 0.661 | |||||
| bHypertension, n (%) | 13 (68.4) | 23 (82.1) | 4 (30.8) | 4 (22.2) | <0.001* | <0.001* | 0.312 | 0.689 |
| bDyslipidemia, n (%) | 10 (52.6) | 13 (46.4) | 2 (15.4) | 5 (27.8) | 0.111 | |||
| bDiabetes, n (%) | 5 (26.3) | 6 (21.4) | 3 (23.1) | 1 (5.6) | 0.376 | |||
| bAtrial fibrillation, n (%) | 4 (21.1) | 9 (32.1) | 1 (7.7) | 1 (5.6) | 0.108 | |||
| bHypertension medication, n (%) | 11 (57.9) | 20 (71.4) | 4 (30.8) | 4 (22.2) | 0.004* | 0.001* | 0.365 | 0.689 |
| bDiabetes medication, n (%) | 4 (21.1) | 6 (21.4) | 3 (23.1) | 0 (0) | 0.126 | |||
| bCholesterol medication, n (%) | 7 (36.8) | 10 (35.7) | 2 (15.4) | 4 (22.2) | 0.468 | |||
| bAnticoagulant or antiplatelet, n (%) | 11 (57.9) | 14 (50) | 1 (7.7) | 2 (11.1) | <0.001* | <0.001* | 0.766 | 1.000 |
| bCurrent smoker, n (%) | 6 (31.6) | 6 (21.4) | 2 (15.4) | 0 (0) | 0.057 | |||
NIHSS, National Institutes of Health stroke scale; SD, standard deviation.
a
Means compared via one-way ANOVA with subsequent planned group-wise comparisons by two-sample two-tailed t-test;
b
Proportions compared via 2×4 Fisher’s exact test with subsequent planned group-wise comparisons by 2×2 Fisher’s exact test;
c
Means compared via two-sample two-tailed t-test.
*
Statistically significant.